Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy + Doravirine Switch in HIV+ Males > 45
NCT04538040Phase 4Completed
- Sponsor
- Quest Clinical Research
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide, doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Quest Clinical Research. Started Dec 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidedoravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04538040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538040.